![FDA, FTC and DOJ Enforcement of Medical Device Regulations FDA, FTC and DOJ Enforcement of Medical Device Regulations](https://www.fdanews.com/ext/resources/Book-Covers-2/BFFDEMDR-COVER.png?height=200&t=1685733565&width=200)
Home » FDA Clears RLF-100 for COVID-19 Trial
FDA Clears RLF-100 for COVID-19 Trial
![FDA clears text](https://www.fdanews.com/ext/resources/test/Drug-Images4/FDA-clears.gif?t=1619732616&width=430)
The FDA has granted Relief Therapeutics and NeuroRx approval for a phase 2/3 trial of inhaled RLF-100 (aviptadil) for the prevention of respiratory failure in patients with moderate to severe COVID-19 infections.
Aviptadil is a synthetic form of a natural peptide that has been shown to block replication of the SARS-CoV-2 coronavirus in human lung cells and immune cells.
The first phase of the trial will enroll patients hospitalized for severe COVID-19 who do not have respiratory failure. If early results are promising, the trial will be expanded to include patients at home with mild and moderate COVID-19.
Upcoming Events
-
21Oct